Literature DB >> 18024218

Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands.

G J G Ruijter1, M J Valstar, J M van de Kamp, R M van der Helm, S Durand, O P van Diggelen, R A Wevers, B J Poorthuis, A V Pshezhetsky, F A Wijburg.   

Abstract

Mucopolysaccharidosis IIIC (MPS IIIC, Sanfilippo C syndrome) is a lysosomal storage disorder caused by deficiency of the lysosomal enzyme acetyl-CoA:alpha-glucosaminide N-acetyltransferase (HGSNAT). We performed a clinical study on 29 Dutch MPS IIIC patients and determined causative mutations in the recently identified HGSNAT gene. Psychomotor development was reported to be normal in all patients during the first year of life. First clinical signs were usually noted between 1 and 6 years (mean 3.5 years), and consisted of delayed psychomotor development and behavioral problems. Other symptoms included sleeping and hearing problems, recurrent infections, diarrhoea and epilepsy. Two sisters had attenuated disease and did not have symptoms until the third decade. Mean age of death was 34 years (range 25-48). Molecular analysis revealed mutations in both alleles for all patients except one. Altogether 14 different mutations were found: two splice site mutations, one frame shift mutation due to an insertion, three nonsense mutations and eight missense mutations. Two mutations, p.R344C and p.S518F, were frequent among probands of Dutch origin representing 22.0% and 29.3%, respectively, of the mutant alleles. This study demonstrates that MPS IIIC has a milder course than previously reported and that both severity and clinical course are highly variable even between sibs, complicating prediction of the clinical phenotype for individual patients. A clear phenotype-genotype correlation could not be established, except that the mutations p.G262R and p.S539C were only found in two sisters with late-onset disease and presumably convey a mild phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024218     DOI: 10.1016/j.ymgme.2007.09.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  52 in total

1.  Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease).

Authors:  J de Ruijter; L Broere; M F Mulder; A T van der Ploeg; M E Rubio-Gozalbo; S B Wortmann; G Visser; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

2.  Co-morbidity of Sanfilippo syndrome type C and D-2-hydroxyglutaric aciduria.

Authors:  M Ali Pervaiz; Marc C Patterson; Eduard A Struys; Gajja S Salomons; Cornelis Jakobs; Devin Oglesbee; Salman Kirmani
Journal:  J Neurol       Date:  2011-03-08       Impact factor: 4.849

3.  Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model.

Authors:  Carla Martins; Helena Hůlková; Larbi Dridi; Virginie Dormoy-Raclet; Lubov Grigoryeva; Yoo Choi; Alexander Langford-Smith; Fiona L Wilkinson; Kazuhiro Ohmi; Graziella DiCristo; Edith Hamel; Jerôme Ausseil; David Cheillan; Alain Moreau; Eva Svobodová; Zuzana Hájková; Markéta Tesařová; Hana Hansíková; Brian W Bigger; Martin Hrebícek; Alexey V Pshezhetsky
Journal:  Brain       Date:  2015-01-06       Impact factor: 13.501

4.  Epidemiology of mucopolysaccharidoses.

Authors:  Shaukat A Khan; Hira Peracha; Diana Ballhausen; Alfred Wiesbauer; Marianne Rohrbach; Matthias Gautschi; Robert W Mason; Roberto Giugliani; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-05-26       Impact factor: 4.797

Review 5.  Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.

Authors:  E M Cross; D J Hare
Journal:  J Inherit Metab Dis       Date:  2013-02-06       Impact factor: 4.982

6.  Novel Direct Assay for Acetyl-CoA:α-Glucosaminide N-Acetyltransferase Using BODIPY-Glucosamine as a Substrate.

Authors:  Yoo Choi; Alexander B Tuzikov; Tatyana V Ovchinnikova; Nicolai V Bovin; Alexey V Pshezhetsky
Journal:  JIMD Rep       Date:  2015-10-23

7.  Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID).

Authors:  Sheena Grant; Elaine Cross; James Edmond Wraith; Simon Jones; Louise Mahon; Michelle Lomax; Brian Bigger; Dougal Hare
Journal:  J Inherit Metab Dis       Date:  2012-11-15       Impact factor: 4.982

8.  Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease.

Authors:  J de Ruijter; L Ijlst; W Kulik; H van Lenthe; T Wagemans; N van Vlies; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

9.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

10.  Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C.

Authors:  Matthew Feldhammer; Stéphanie Durand; Alexey V Pshezhetsky
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.